Company Profile
Lexicon Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- LXRX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.34 USD (+4.93%)
Close
Last updated: July 28, 2026
840M USD
Market cap
Why the stock is moving
Following the latest company update, “Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)”, LXRX closed down 2.62% at $2.23 on Jul 27, 2026. The move occurred in the trading session associated with this clinical readout update.
Company overview
Business overview
Lexicon Pharmaceuticals is a specialty pharmaceutical company with programs in cardiometabolic and other chronic diseases. Its business has been shaped by both commercial execution and pipeline reset.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Lexicon sits in specialty biopharma.
Business Model Characteristics
The model depends on commercial products, development optionality, and the ability to stabilize its growth profile.
Position Within the Biotechnology Landscape
Lexicon is a turnaround-sensitive specialty-pharma name with catalyst risk around pipeline and execution.
Future catalysts
Lexicon Pharmaceuticals's catalysts are sotagliflozin commercialization and the rest of the metabolic and cardiac pipeline. The company improves when the commercial base looks more durable.
Recent news
- 01
- 02
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
Source: Lexicon Pharmaceuticals
- 03
Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
Source: Lexicon Pharmaceuticals
- 04
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
Source: Lexicon Pharmaceuticals
- 05
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
Source: Lexicon Pharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Lexicon Pharmaceuticals (LXRX)?
Lexicon Pharmaceuticals (LXRX) most recently closed at 2.34 USD, a +4.93% move versus the previous session.
What is the market cap of Lexicon Pharmaceuticals (LXRX)?
Lexicon Pharmaceuticals currently has a market capitalization of 840M USD on BioPharmSignal.
What does Lexicon Pharmaceuticals do?
Lexicon Pharmaceuticals is a specialty pharmaceutical company with programs in cardiometabolic and other chronic diseases. Its business has been shaped by both commercial execution and pipeline reset.
On which exchange is LXRX stock listed?
Lexicon Pharmaceuticals (LXRX) is associated with NASDAQ, United States, Biopharma.
What is Lexicon?
Lexicon Pharmaceuticals's catalysts are sotagliflozin commercialization and the rest of the metabolic and cardiac pipeline.
Which conditions is Lexicon Pharmaceuticals targeting with Lexicon?
Lexicon Pharmaceuticals is associated with metabolic disease based on its company overview and current catalyst commentary.
How does Lexicon Pharmaceuticals describe recent progress with Lexicon?
Lexicon Pharmaceuticals's catalysts are sotagliflozin commercialization and the rest of the metabolic and cardiac pipeline.
What is Pharmaceuticals?
Lexicon Pharmaceuticals is a specialty pharmaceutical company with programs in cardiometabolic and other chronic diseases.